AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline

AC Immune SA ( (ACIU) ) has provided an update.

On April 30, 2026, AC Immune reported first-quarter 2026 financial and corporate updates, highlighting a cash position of CHF 74.8 million as of March 31, 2026, providing runway into the fourth quarter of 2027 and reflecting reduced R&D spending after pipeline prioritization. The company advanced several key programs, including dosing first subjects in a Phase 1 trial of NLRP3 inhibitor ACI-19764, initiating the final AD4 cohort in the ABATE Phase 1b/2 ACI-24 Alzheimer’s trial that triggers a milestone from Takeda, presenting promising interim Phase 2 data for Parkinson’s vaccine ACI-7104 and first-in-human TDP-43 PET images, and amending its Morphomer Tau deal with Eli Lilly to secure new funding and expand development, positioning AC Immune for multiple value-driving data readouts and IND-enabling milestones in 2026.

R&D expenses declined year-on-year to CHF 11.8 million while G&A remained stable at CHF 4.2 million, underscoring tighter cost control as late-stage trials progress and collaborations deepen. With a CHF 10 million upfront payment from Lilly expected in the second quarter of 2026 and potential additional milestones from partners, the company appears better capitalized to pursue its broad neurodegeneration pipeline, although future value will depend on upcoming Phase 2 efficacy data and early safety and biomarker results from its small molecule and vaccine programs.

The most recent analyst rating on (ACIU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.

Spark’s Take on ACIU Stock

According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.

The score is held back primarily by ongoing unprofitability and the 2025 shift back to significant cash burn alongside declining revenue and erosion of equity, despite the offsetting benefit of low leverage. Technically, the stock sits slightly above key moving averages but lacks positive momentum (negative MACD and sub-50 RSI). Valuation support is limited given the negative P/E and no dividend yield.

To see Spark’s full report on ACIU stock, click here.

More about AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, focused on precision therapeutics and diagnostics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its pipeline includes active immunotherapies, small molecule aggregation inhibitors and PET tracers, developed in partnership with major pharma groups including Takeda, Eli Lilly and Janssen, with a particular emphasis on targeting pathological proteins like Abeta, Tau, alpha-synuclein and TDP-43.

Average Trading Volume: 279,848

Technical Sentiment Signal: Sell

Current Market Cap: $298.2M

For an in-depth examination of ACIU stock, go to TipRanks’ Overview page.